The widespread adoption of multi-cancer early detection (MCED) tests would inevitably have implications for life and health (L&H) insurers, said Swiss Re Institute.
If you are already a subscriber
OR sign-up for a trial access here
Note that your comment may be edited or removed in the future, and that your comment may appear alongside the original article on websites other than this one.
more »
Brought to you by